HOME >> MEDICINE >> NEWS
BioNumerik Reports Preclinical Antitumor Data On Two Novel Supercomputer Engineered Anticancer Agents At 89th Annual AACR Conference

tives. These results also demonstrate the ability of BioNumerik's Karenitecins to bypass common drug resistance mechanisms (MDR, MRP & LRP) to which many other camptothecins appear to be susceptible. Because its compounds are lipophilic, BioNumerik believes its Karenitecins will have enhanced tissue penetration, drug delivery and bioavailability compared to water soluble camptothecins.

Camptothecins, described as Topoisomerase I inhibitors, represent some of the most active anticancer drugs in existence. Due to formulation problems, however, the great majority of camptothecins in development or on the market have been made water soluble to allow easier drug dissolution and administration. BioNumerik believes that this approach may limit the utility of these drugs and the Company has developed a new generation of proprietary highly lipophilic (fat loving) camptothecins, known as Karentitecins, that have been designed to overcome problems that exist with camptothecin and the current camptothecin derivatives.

Using its mechanism-based approach, BioNumerik used its Cray supercomputers to construct a detailed computational model involving human Topoisomerase I and DNA in order to understand and more precisely target the key interactions between camptothecin-Topo I/DNA. BioNumerik used this information to guide and complement the discovery and optimization of novel compounds for laboratory synthesis and preclinical testing.

In a presentation titled "BNP7787: Administration In Vivo Results in Increased Therapeutic Index and Toxicity Reduction of Platinum Drugs", BioNumerik also presented data on its proprietary agent BNP7787, a novel water soluble disulfide that was engineered to increase the therapeutic index of cisplatin and carboplatin, two widely used anticancer drugs.

Although platinum chemotherapy is widespread, formulations of cisplatin and carboplatin have a major risk of kidney toxicity (cisplatin), nausea and vomiting, bone marrow suppressio
'"/>

Contact: Neil Cohen
neil@noonanrusso.com
212-696-4455 x. 205
Noonan/Russo Communications
30-Mar-1998


Page: 1 2 3 4 5

Related medicine news :

1. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
2. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
5. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
6. UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer
7. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
8. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
9. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
10. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
11. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports

Post Your Comments:
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... the specialty in which the physician is board-certified is increasingly influential in their ... Dermatologic Surgery. , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures reflects ...
(Date:8/4/2015)... ... ... (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio and Kentucky – has ... high school athletes for fall sports. , In a concise video on Mercy Health’s ... What steps to take to help prevent injuries , How to see ...
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years ... their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas ... other. Following the ceremony was a reception, with music by the Moonlight Serenade ...
(Date:8/4/2015)... ... , ... The goal of looking younger – with a fresher, more rested ... this ideal is not. But minimally invasive procedures such as dermal fillers, tighteners or ... recovery time, according to Valerie Goldburt, MD, PhD , of Advanced Dermatology ...
(Date:8/4/2015)... ... August 04, 2015 , ... In the most ... Johnson & Johnson report that a new location for pretrial proceedings is under ... updates and cancer warning information at their website, the Talcum Powder Cancer Lawsuit ...
Breaking Medicine News(10 mins):Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... , Aug. 3, 2015  LEO Pharma supports the ... (FDA) to include psoriasis as one of eight priority ... Initiative i .  Psoriasis is an autoimmune disease that ... comorbidities, affecting 7.5 million people in the US alone. ... ongoing commitment to supporting patients living with psoriasis, LEO ...
(Date:8/3/2015)... BUFFALO, N.Y. , Aug. 3, 2015 /PRNewswire/ ... the Wilmot Cancer Institute to the OmniSeq SM ... from Roswell Park Cancer Institute (RPCI) and announced ... products that support a physician-driven, collaborative approach to ... patient outcomes.  Wilmot Cancer Institute is a rapidly ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
Cached News: